NASDAQ:ARCT Arcturus Therapeutics (ARCT) Stock Price, News & Analysis $8.36 -0.08 (-0.95%) Closing price 04:00 PM EasternExtended Trading$8.37 +0.01 (+0.12%) As of 06:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Arcturus Therapeutics Stock (NASDAQ:ARCT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Arcturus Therapeutics alerts:Sign Up Key Stats Today's Range$8.12▼$8.6850-Day Range$8.44▼$16.9352-Week Range$5.50▼$17.96Volume377,106 shsAverage Volume631,769 shsMarket Capitalization$240.94 millionP/E RatioN/ADividend YieldN/APrice Target$24.50Consensus RatingBuy Company Overview Arcturus Therapeutics Holdings Inc. is a biotechnology company founded in 2013 and headquartered in San Diego, California. It develops RNA medicines and vaccines, using its LUNAR lipid-mediated delivery technology and self-amplifying RNA platform to deliver genetic instructions to cells. The company’s pipeline includes investigational treatments for rare diseases, such as ARCT-032 for cystic fibrosis and ARCT-810 for ornithine transcarbamylase deficiency. It has also developed ARCT-154, a self-amplifying mRNA COVID-19 vaccine approved in Japan as Kostaive, and works with partners on the development and commercialization of its products. Arcturus focuses on genetic medicines and vaccines for patients in the United States and international markets. Its research spans respiratory and metabolic disorders as well as infectious diseases.AI Generated. May Contain Errors. Read More Arcturus Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks58th Percentile Overall ScoreARCT MarketRank™: 2.88376046025 of 5 starsArcturus Therapeutics scored higher than 58% of companies evaluated by MarketBeat, and ranked 427th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingArcturus Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 6 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialArcturus Therapeutics has a consensus price target of $24.50, representing about 191.7% upside from its current price of $8.40.Amount of Analyst CoverageArcturus Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Arcturus Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Arcturus Therapeutics are expected to decrease in the coming year, from ($2.96) to ($3.32) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arcturus Therapeutics is -2.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arcturus Therapeutics is -2.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArcturus Therapeutics has a P/B Ratio of 1.44. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted23.15% of the float of Arcturus Therapeutics has been sold short.Short Interest Ratio / Days to CoverArcturus Therapeutics has a short interest ratio ("days to cover") of 7.37.Change versus previous monthShort interest in Arcturus Therapeutics has recently decreased by 0.92%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldArcturus Therapeutics does not currently pay a dividend.Dividend GrowthArcturus Therapeutics does not have a long track record of dividend growth. News and Social Media2.1 / 5News Sentiment0.42 News SentimentArcturus Therapeutics has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Arcturus Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 3 people have searched for ARCT on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Arcturus Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders17.80% of the stock of Arcturus Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions94.54% of the stock of Arcturus Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Arcturus Therapeutics' insider trading history. Receive ARCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arcturus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ARCT Stock News HeadlinesArcturus: 'Hold' On Next-Gen ARCT-2601 OTC Candidate And Continued CF AdvancementNovember 9, 2026 | seekingalpha.comArcturus Therapeutics (NASDAQ:ARCT) Upgraded to Hold at Wall Street ZenNovember 7, 2026 | americanbankingnews.com$0. Later: $29.97.Bill Poulos is giving away his Simple Options Trading For Beginners book through a temporary link. Once that link expires, it returns to its usual price of $29.97. The content stays the same - plain-English lessons and a handful of proven techniques - only the price changes. Waiting means paying for something you could have gotten for free.November 13 at 1:00 AM | Profits Run (Ad)Arcturus (ARCT) Q3 2026 Earnings Call TranscriptNovember 6, 2026 | finance.yahoo.comArcturus Therapeutics Holdings Inc. (ARCT) Q3 2026 Earnings Call TranscriptNovember 6, 2026 | seekingalpha.comArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Stock Has Consensus Target Price of $22.29 According to BrokeragesNovember 5, 2026 | americanbankingnews.comEarnings To Watch: Arcturus Therapeutics Holdings Inc (ARCT) Q3 2026 -- GF Value Sees 59% DownsideNovember 4, 2026 | finance.yahoo.comArcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 5, 2026October 26, 2026 | finance.yahoo.comSee More Headlines ARCT Stock Analysis - Frequently Asked Questions How have ARCT shares performed this year? Arcturus Therapeutics' stock was trading at $6.13 at the beginning of the year. Since then, ARCT shares have increased by 37.0% and is now trading at $8.40. How were Arcturus Therapeutics' earnings last quarter? Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) posted its quarterly earnings results on Thursday, November, 5th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.69) by $0.43. The biotechnology company earned $18.30 million during the quarter, compared to analyst estimates of $8.00 million. Arcturus Therapeutics had a negative net margin of 285.92% and a negative trailing twelve-month return on equity of 46.79%. Read the conference call transcript. Who are Arcturus Therapeutics' major shareholders? Top institutional shareholders of Arcturus Therapeutics include Sumitomo Mitsui Trust Group Inc. (5.94%), State Street Corp (2.07%), Russell Investments Group Ltd. (0.25%) and Alps Advisors Inc. (0.13%). View institutional ownership trends. How do I buy shares of Arcturus Therapeutics? Shares of ARCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Arcturus Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Arcturus Therapeutics investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Editas Medicine (EDIT), NIO (NIO), Block (XYZ) and Alibaba Group (BABA). Company Calendar Last Earnings11/05/2026Today11/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 2 weeks, ARCT's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ARCT CIK1768224 Webwww.arcturusrx.com Phone(858) 900-2660FaxN/AEmployees111Year Founded2013Price Target and Rating Average Price Target for Arcturus Therapeutics$24.50 High Price Target$41.00 Low Price Target$19.00 Potential Upside/Downside+193.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($3.08) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$65.78 million Net Margins-285.92% Pretax Margin-285.93% Return on Equity-46.79% Return on Assets-36.50% Debt Debt-to-Equity RatioN/A Current Ratio6.68 Quick Ratio6.68 Sales & Book Value Annual Sales$82.03 million Price / Sales2.94 Cash FlowN/A Price / Cash FlowN/A Book Value$5.85 per share Price / Book1.43Miscellaneous Outstanding Shares28,820,000Free Float23,693,000Market Cap$240.94 million OptionableOptionable Beta2.62 Social Links Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:ARCT) was last updated on 11/13/2026 by MarketBeat.com Staff. From Our PartnersTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcturus Therapeutics Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcturus Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
